- Home
- UAMY vs NEO Comparison
UAMY vs NEO Comparison
Compare UAMY & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UAMY | NEO |
|---|---|---|
| Founded | 1968 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Precision Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1997 | 2008 |
Fundamental Metrics
Financial Performance| Metric | UAMY | NEO |
|---|---|---|
| Price | $6.51 | $14.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $9.44 | ★ $13.38 |
| AVG Volume (30 Days) | ★ 6.6M | 3.7M |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,257,708.00 | N/A |
| Revenue This Year | $219.89 | $10.63 |
| Revenue Next Year | $104.28 | $9.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 162.80 | N/A |
| 52 Week Low | $2.80 | $4.72 |
| 52 Week High | $19.71 | $15.57 |
Technical Indicators
Market Signals| Indicator | UAMY | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 38.01 | 63.47 |
| Support Level | $5.98 | $11.49 |
| Resistance Level | $6.95 | N/A |
| Average True Range (ATR) | 0.54 | 0.73 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 6.93 | 68.58 |
Price Performance
Historical ComparisonAbout UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the Domestic, Canada, and Mexico, of which the vast majority of its revenue comes from the Domestic.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.